US Patent Issued to CLEXIO BIOSCIENCES on July 22 for "Esketamine for use in treating major depressive disorder" (Israeli Inventor)

ALEXANDRIA, Va., July 23 -- United States Patent no. 12,364,672, issued on July 22, was assigned to CLEXIO BIOSCIENCES LTD. (Yokne'am, Israel).

"Esketamine for use in treating major depressive disorder" was invented by Elena Kagan (Givat Shaul, Israel).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides a dosage regimen for safe and efficacious administration of esketamine and rapid-acting antidepressants in the treatment of major depressive disorder (MDD)."

The patent was filed on Oct. 11, 2019, under Application No. 17/284,131.

*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fne...